Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jon Oliner"'
Publikováno v:
Cancer Research. 83:2386-2386
Live tumor fragments (LTF) that maintain a patient's relevant tumor microenvironment provides an opportunity to study treatment response. To verify viability of the fragments over time, we have devised and applied a label-free quantitative microscopy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b32e8d9db51fe29ee0d238315c525c83
https://doi.org/10.1158/1538-7445.am2023-2386
https://doi.org/10.1158/1538-7445.am2023-2386
Autor:
Michael B. Atkins, David C. Alsop, Xiaoen Wang, Dongyin Yu, Andrea J. Bullock, James W. Mier, Rupal S. Bhatt, Kedar Mahagaokar, Liang Zhang, Angela Coxon, Lin Wei, Jon Oliner
Publikováno v:
Translational Oncology
Angiopoietin 2 (Ang2) is a secreted glycoprotein upregulated at sites of angiogenesis and has been implicated in cancer neovascularization. Recent studies have suggested efficacy of combined Ang and vascular endothelial growth factor receptor (VEGFR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33ce222eb237b20feeb026e7b46ad677
https://pubmed.ncbi.nlm.nih.gov/24704536
https://pubmed.ncbi.nlm.nih.gov/24704536
Autor:
Jon Oliner, Jodi Moriguchi, Angela Coxon, H. Toni Jun, Dave Cordover, Steve Kaufman, Charlie Starnes, Bethany Mattson
Publikováno v:
Cancer Research. 74:2991-2991
Bevacizumab is a monoclonal antibody targeting VEGF that is clinically approved for the treatment of multiple indications in oncology, including colorectal, lung and renal cancer as well as glioblastoma. Clinical activity has also been demonstrated i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df1bdbb74b7da680f169b62259797756
https://doi.org/10.1158/1538-7445.am2014-2991
https://doi.org/10.1158/1538-7445.am2014-2991
Autor:
Jon Oliner, James Bready, Juan Estrada, Kyung Ryul Lee, Kevin Graham, Angela Coxon, Stephen Kaufman, Dongyin Yu, Rick Jacobsen
Publikováno v:
Cancer Research. 74:1022-1022
Targeting the angiopoietins with trebananib (a peptibody that inhibits the interaction between the endothelial cell-selective Tie2 receptor and its ligands Ang1 and Ang2) in combination with paclitaxel was associated with clinical benefit in a phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f52d5ab55d832e1dd7d5b299dfdd267
https://doi.org/10.1158/1538-7445.am2014-1022
https://doi.org/10.1158/1538-7445.am2014-1022
Autor:
Andrea J. Bullock, Xiaoen Wang, Michael B. Atkins, James W. Mier, Manoj Bhasin, Dongyin Yu, Rupal S. Bhatt, David C. Alsop, Angela Coxon, Jiaxi Song, Sabina Signoretti, Liang Zhang, Lin Wei, Jon Oliner
Publikováno v:
Cancer Research. 73:1608-1608
Background: Several small molecules targeting angiogenic receptor tyrosine kinases (TKIs) are approved for treatment of advanced RCC. While many patients (pts) respond to TKIs, resistance develops in all. Ang2 is a secreted glycoprotein that is upreg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb983d1f491b1604f9f3fdb6607f67ff
https://doi.org/10.1158/1538-7445.am2013-1608
https://doi.org/10.1158/1538-7445.am2013-1608
Autor:
Oliner JD; Jon Oliner Consulting, Garrett Park, Maryland 20896., Saiki AY; Oncology Research, Amgen, Thousand Oaks, California 91320., Caenepeel S; Oncology Research, Amgen, Thousand Oaks, California 91320.
Publikováno v:
Cold Spring Harbor perspectives in medicine [Cold Spring Harb Perspect Med] 2016 Jun 01; Vol. 6 (6). Date of Electronic Publication: 2016 Jun 01.